Friday, 16 October 2026European Markets

ELECT. MADAGASCAR Stock Rises By 15% In The Last 5 Sessions

Loading stream...

electricite et eaux de madagascar soceite anonyme (elect. madagascar), listed on cac 40 as eem.pa, experienced a significant surge over the past week. despite previous losses and a declining cac 40, the company made a remarkable comeback, surging 15.32% over five sessions to eur2.86 on friday.

elect. madagascar background and rankings

established since 1928, elect. madagascar operates in multiple sectors, including the luxury hotel business, real estate development, paper production, and casino operations in cambodia. the company's diversity didn't prevent a troubled financial performance, however, as its trailing twelve-month eps report indicates a loss with eur-0.48.

trading volume and price volatility

despite the sharp climb in share price, trading activity was remarkably low. elect. madagascar saw a reported volume of only four shares today, which is 95.34% below its average volume of 86 shares per day. this low trading activity may suggest poor investor sentiment or liquidity issues, which can contribute to greater price volatility.

indications of increased volatility

indeed, elect. madagascar's history shows significant fluctuations in volatility. the average intraday variations over the last week, month, and quarter were positive 6.56%, negative 1.53%, and positive 5.61%, respectively. this high amplitude volatility indicates potential risks and opportunities for investors.

potential reversal indicator

interestingly, despite its recent surge, this stock remains oversold, as indicated by its stochastic oscillator reading of less than or equal to 20. this suggests a strong selling pressure that could trigger a turnaround if buyers find value at these levels. therefore, understanding individual stock dynamics as well as indications like volatility and stochastic oscillators is crucial for making informed investment decisions.

more news about elect. madagascar (eem.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com